Russia announced that its second vaccine for the emerging corona virus "Covid-19" is 100% effective, according to "Reuters" (Reuters), according to "TASS" agency, and according to what was published by "Sputnik" agency (sputnik).
Russia's Consumer Health Monitoring Authority (Rospotrebnadzor) said today, Tuesday, that Russia's second vaccine against Covid-19, named "EpiVacCorona", is 100% effective based on the results of clinical trials.
Russia began conducting clinical trials for Epivac Corona last November.
A report by Sputnik said that the vaccine was developed by the "Vector State Research Center of Virology and Biotechnology" outside the Russian city of Novosibirsk.
He added that the immune effectiveness of the vaccine reaches 100%, based on the results of the first and second stages of clinical trials, according to the Consumer Health Monitoring Authority in Russia, "the Federal Service for Monitoring the Protection of Consumer Rights and Human Welfare."
The authority said in a statement that "the overall effectiveness of the vaccine consists of its immunological and preventive action."
Unlike the first Russian vaccine, "Sputnik-V", which is a vector vaccine based on a human adenovirus, the vaccine "EpiVacCorona" is a peptide-based drug, and it consists of short, synthetically synthesized parts of proteins. Viral "peptides", through which the immune system learns to recognize the virus and then neutralize it.
The Russian Deputy Prime Minister, Tatyana Golikova, said last October, "I must say that the vaccine is characterized by the absence of interaction (side reactions) and a high level of safety."
And this at a time when clinical trials began on it after registration in various Russian regions with the participation of 40,000 volunteers.
The Russian public health chief, Anna Popova, confirmed that the documents related to Epivac Corona were submitted to the World Health Organization on December 8, and “we are awaiting the decision of the World Health Organization.”